Chennai, Oct 24: The city-based Huclin Research Limited (HRL), an independent clinical research organization (CRO), today announced commencement of a full array of clinical research activities to cater to pharmaceutical and biotechnology companies.
Strategically located in TICEL Bio-Park, HRL would provide high standard quality clinical research services like design and conduct of Bioavailability, Bioequivalence studies, including fasting study, food effect study, Pharmacokinetic and Pharmacodynamic (PK-PD) studies, individual bioequivalence and special population studies.
HRL has installed sophisticated, advanced and automated equipments for the bio-analytical lab.
HRL Executive Director Mahalingam Vasudevan said the company had invested Rs seven crore for setting up a bio-analytical facility and clinical beds at Ticel Bio-Park.
In the second phase, an additional Rs 15 crore will be spent on developing multi-centric trial centers across India, a HRL release said.
The company has also created quality infrastructure to conduct clinical trial services including the design and conduct of phase I to IV studies, protocol design and development, optimizing clinical trial design and patient population, designing of case record form (CRF and design and development of Patient Information Leaflets (PIL) and Quality of Life (QoL) forms.